



Clinical Practice Policy:	Target O2 Sats for Infants in the Neonatal Intensive Care Unit
Effective Date:	August 11, 2015

I. Purpose

To provide a clinical practice policy (CPP) for optimal oxygen saturation targets for babies in the Newborn Intensive Care Unit.

II. All CPPs reflect the [NICU Nursing Standards of Care](#). All relevant nursing policies, procedures, and guidelines (PPGs) are listed below.

- [WNH O.2 Emergency Administration of O2 to Infants](#)
- [NICU O.4 High Flow and Low Flow O2 Administration via Nasal Cannula](#)
- [NICU M.2 Monitoring](#)

III. Exclusions

Babies with persistent pulmonary hypertension, congenital heart disease of the newborn, or on inhaled nitric oxide therapy.

IV. Summary

Oxygen can be a life saving therapy for sick and preterm newborns in the intensive care unit. Five large multi center trials aiming to define optimal SpO2 targets in preterm babies have shown that targeting SpO2 in the low range (85-89%) is associated with an increase in mortality and NEC compared to the higher range (91-95%). Although babies maintained in the lower range of SpO2 had a lower incidence of severe ROP there were no significant differences in the incidence of blindness. There was also no major difference in the combined outcomes of death or major disability. Based on this data the European consensus data recommends target O2 sats of 90-95% in preterm babies. In order to provide the best care to our babies it is important to define a target O2 sat range that limits morbidity while not causing any increase in mortality. We also want to provide realistic monitor sat limits that will be practical and minimize undue alarms. Based on the best available evidence the recommended target O2 sats/monitor limits are as follows

Gestational age	Target O2 sats/sat limit when on O2	Target O2 sats/sat limit when off O2
Gestational age <32 weeks	90-95%	90-100%
Gestational age 32-36 weeks	92-97%	92-100%
Gestational age >36 weeks	94-98%	94-100%



V. Points of Emphasis

- The oximeter must be able to detect an adequate pulse rate and waveform.
- Conditions that can interfere with the monitor's ability to detect arterial pulsations include: compromised cardiac output, hypotension, marked edema, motion artifact, poor cable connection, phototherapy lights, poor disposable probe sensor (may need to be replaced), or the probe site may need to be changed.
- Infants should **always** receive supplemental oxygen through an oxygen blender.
- Infants with congenital heart disease may need individualized goal SpO₂ ranges based on their anatomy and physiology. The physician orders should reflect this after discussion with Pediatric Cardiology.
- If the infant's SpO₂ reading is consistently in the high range, the FiO₂ should be weaned.
- Infants receiving supplemental oxygen (CPAP, ventilator) who have an oxygen requirement which increases by 10% should be re-assessed by the medical staff.
- The infant receiving supplemental oxygen via a nasal cannula, whose oxygen requirement increases significantly beyond their baseline, should be reassessed by the medical or NNP staff.
- When the infant no longer requires supplemental oxygen, discuss discontinuing O₂ and/or oximetry with the physician. An order should be placed **prior** to discontinuing oximetry.

- **Strategies to limit oxygen toxicity**
 - o Ensure monitor alarm limits are set for ranges per policy
 - o If a baby previously on O₂ comes off Oxygen the upper limits should not be changed to 100% unless the pt remains in room air > 6 hrs
 - o If a baby previously in RA FiO₂ needs additional O₂ for greater than 6 hrs the sat limits be changed to the age appropriate ranges
 - o Daily attending progress note should include:
 - a) Diagnosis
 - b) FiO₂
 - c) If any reason to deviate from target O₂ sat limits.



VI. References

1. Sprague D., et al., "A new system to record reliable pulse oximetry data from the Nellcor N-200 and its applications in studies of variability in infant oxygenation".
J Clin Monitoring 1996; 12:17-25.
2. Vijayakumar E., et al., "Pulse oximetry in infants of <1500 gm birth weight on supplemental oxygen: A national survey". J Perinatol 1997; 17:341-5.
3. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. "Target ranges of oxygen saturation in extremely preterm infants". N Engl J Med. Author manuscript; available in PMC 2010 November 27.
4. Saugstad OD, Aune D. "Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies". Neonatology 2014; 105(1):55-63.
5. Manja V, et al. "Oxygen saturation target range for extremely preterm infants: A systematic review and meta-analysis". JAMA Pediatr 2015, 1;169(4):332-40.
6. BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New Zealand Collaborative Group, Stenson BJ, Tarnow-Mordi WO, Darlow BA, Simes J, Juszczak E, Askie L, Battin M, Bowler U, Broadbent R, Cairns P, Davis PG, Deshpande S, Donoghoe M, Doyle L, Fleck BW, Ghadge A, Hague W, Halliday HL, Hewson M, King A, Kirby A, Marlow N, Meyer M, Morley C, Simmer K, Tin W, Wardle SP, Brocklehurst P. "Oxygen saturation and outcomes in preterm infants". N Engl J Med. 2013 May 30;368(22):2094-104.
7. Vaucher YE, Peralta-Carcelen M, Finer NN, Carlo WA, Gantz MG, Walsh MC, Laptook AR, Yoder BA, Faix RG, Das A, Schibler K, Rich W, Newman NS, Vohr BR, Yolton K, Heyne RJ, Wilson-Costello DE, Evans PW, Goldstein RF, Acarregui MJ, Adams-Chapman I, Pappas A, Hintz SR, Poindexter B, Dusick AM, McGowan EC, Ehrenkranz RA, Bodnar A, Bauer CR, Fuller J, O'Shea TM, Myers GJ, Higgins RD; SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. "Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial". N Engl J Med. 2012 Dec 27;367(26):2495-504
8. Schmidt B, Whyte RK, Asztalos EV, Moddemann D, Poets C, Rabi Y, Solimano A, Roberts RS; Canadian Oxygen Trial (COT) Group. "Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial". JAMA. 2013 May 22;309(20):2111-20